<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227682</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000443708</org_study_id>
    <secondary_id>OHSU-1277</secondary_id>
    <secondary_id>OHSU-HEM-03100-L</secondary_id>
    <secondary_id>P30CA069533</secondary_id>
    <nct_id>NCT00227682</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, dexamethasone, and ascorbic&#xD;
      acid, work in different ways to stop the growth of cancer cells, either by killing the cells&#xD;
      or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may&#xD;
      kill more cancer cells. Sometimes when chemotherapy is given, it does not stop the growth of&#xD;
      cancer cells. The cancer is said to be resistant to chemotherapy. Giving arsenic trioxide&#xD;
      together with chemotherapy may reduce drug resistance and allow the cancer cells to be&#xD;
      killed. Thalidomide may stop the growth of multiple myeloma by blocking blood flow to the&#xD;
      cancer. Giving arsenic trioxide together with thalidomide, dexamethasone, and ascorbic acid&#xD;
      may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with&#xD;
      thalidomide, dexamethasone, and ascorbic acid works in treating patients with relapsed or&#xD;
      refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and side effects of arsenic trioxide administered in combination&#xD;
           with thalidomide, dexamethasone, and ascorbic acid in patients with relapsed or&#xD;
           refractory multiple myeloma.&#xD;
&#xD;
        -  Determine, preliminarily, the anticancer effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the duration of anticancer effects in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the effect of this regimen on bone and immune function in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive arsenic trioxide IV continuously and oral ascorbic acid once daily&#xD;
      on days 1-5 in week 1 and twice weekly in weeks 2-12 and oral thalidomide once daily in weeks&#xD;
      1-14. Treatment with arsenic trioxide, ascorbic acid, and thalidomide repeats every 14 weeks&#xD;
      for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      also receive oral dexamethasone once daily on days 1-4. Treatment with dexamethasone repeats&#xD;
      every 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to funding suspension by grant sponsor.&#xD;
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (complete response, partial response, and minimal response) as measured by bone marrow aspirate, biopsy, cytogenetic analysis, serum, urine, and immunofixation skeletal survey at 6 months and end of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by physical exams, blood tests, and adverse events reports weekly</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma (MM)&#xD;
&#xD;
               -  Relapsed or refractory disease&#xD;
&#xD;
          -  Monoclonal immunoglobulin spike by serum electrophoresis of ≥ 1 gm/dL AND/OR urine&#xD;
             monoclonal immunoglobulin spike of ≥ 200 mg/24 hours&#xD;
&#xD;
          -  Has received ≥ 2 prior treatment regimens for MM&#xD;
&#xD;
          -  None of the following are allowed:&#xD;
&#xD;
               -  Non-secretory MM&#xD;
&#xD;
               -  Plasma cell leukemia&#xD;
&#xD;
               -  Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin&#xD;
                  changes (POEMS) syndrome&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3 (30,000/mm^3 if the bone marrow is extensively&#xD;
             infiltrated)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 3.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiac disease, including any of the following conditions:&#xD;
&#xD;
               -  History of recurrent supraventricular arrhythmia&#xD;
&#xD;
               -  History of sustained ventricular tachycardia&#xD;
&#xD;
               -  History of second or third degree AV block&#xD;
&#xD;
               -  History of left bundle branch block&#xD;
&#xD;
               -  Cardiomyopathy with LVEF &lt; 40%&#xD;
&#xD;
               -  Uncontrolled ischemic heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No prolonged QT interval &gt; 500 ms&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No neuropathy &gt; grade 3&#xD;
&#xD;
          -  Potassium ≥ 4 mEq/L&#xD;
&#xD;
          -  Magnesium ≥ 1.8 mg/dL&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Simic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>May 24, 2012</last_update_submitted>
  <last_update_submitted_qc>May 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

